Kestra Medical Technologies, Ltd. (KMTS)

Nasdaq: KMTS · Surgical & Medical Instruments & Apparatus · Kirkland, WA · filing with the SEC since 2021

Full chart Alerts Compare

Grade5.8

◀ Past 6.4● Present 5.5▶ Future 5.6

3 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Kestra Medical Technologies, Ltd.

Nine metrics read from its own filings, by tense

Headline grade

5.8/10

◀ Past6.430% of the headline

● Present5.540% of the headline

▶ Future5.630% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

6.4/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

8.3/10

Has it survived what it has been through?

No warning events in its filings since 2021.

weight 33% of this tense · 83rd percentile among 121 sector filers · read for itself

From the record

Kestra Medical Technologies, Ltd.'s filings since 2021 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

7.1/10

What has it actually done, year after year?

+85% a year over 3 filed years; profitable in 0 of 3.

weight 45% of this tense · 71st percentile among 105 sector filers · read for its customers

From the record

Kestra Medical Technologies, Ltd.'s 3 filed years say what it did: revenue went from $28 million in fiscal 2024 to $95 million in fiscal 2026, up 85% a year; it rose in 2 of 2 years; it never fell from a peak; net income was positive in 0 of 3 of those years (its annual reports).

What it rests on

revenue growth over the filed span85.0%top 8% of its family
the share of years revenue rosetop 15% of its family
the share of filed years with a profitbottom 23% of its family
the deepest fall from a revenue peak0.0%top 16% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

2.2/10

How has it treated the people who own it?

SI estimate 2.2/10, confidence 35 of 100 (one part).

weight 22% of this tense · 22nd percentile among 120 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 22% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 120 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Kestra Medical Technologies, Ltd.'s shareholder treatment is put at 2.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 22% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.5/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

3.8/10

Is it financially healthy right now?

ROE -51%: lost 51¢ per shareholder dollar. Leverage 28%: owes 28¢ per asset dollar.

weight 45% of this tense · 38th percentile among 120 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2026-04-30, Kestra Medical Technologies, Ltd. lost about 51 cents for every dollar of shareholders' money, and gross profitability: its products earned about 14 cents per dollar of everything the company owns. Leverage: it owed about 28 cents per dollar of assets, and net share issuance: its share count grew 120.4% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 33% of its family
return on equitybottom 43% of its family
gross profit against assetsbottom 21% of its family
the share count against the year beforebottom 19% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

5.5/10

How strong is its position in its industry?

top 45% of 109 in its family; net margin -138.4%.

weight 33% of this tense · 55th percentile among 109 sector filers · read for its customers

From the record

Kestra Medical Technologies, Ltd.'s standing among 109 graded names in its industry family: revenue of $95 million in fiscal 2026 ranks in the top 47% by size; a net margin of -138.4% ranks in the bottom 22%; revenue growth of 85% a year over the last 2 filed years ranks in the top 8% (its annual reports).

What it rests on

revenue against the family$95.1Mtop 47% of its family
net margin-138.4%bottom 22% of its family
three-year revenue growth85.0%top 8% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

9.1/10

What are the people in charge doing?

SI estimate 9.1/10, confidence 35 of 100 (one part).

weight 22% of this tense · 91st percentile among 108 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 9% of 108 in its family; the record of its people begins on 2025-03-06 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 1.7 years and cannot see past it; a floor under five years is not read as years in charge.
What the record cannot read: The record of its people begins on 2025-03-06 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 1.7 years and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: one part: officer and director changes on Form 8-K, against the people in charge, the one part on file, ranked among 108 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Kestra Medical Technologies, Ltd.'s leadership is put at 9.1 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 9% of 108 in its family; the record of its people begins on 2025-03-06 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 1.7 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

5.6/1030% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed

4.3/10

How much room does it have to grow?

bottom 43% of 104 in its family for room to expand.

weight 45% of this tense · 43rd percentile among 104 sector filers · read for itself

From the record

Kestra Medical Technologies, Ltd.'s room to grow, from the newest filed statements (fiscal 2026): cash of $100 million against debt of $43 million leaves 16% of its assets as net cash, top 43% of its family; cash from operations less capital spending is -122.6% of revenue (bottom 19%); a gross margin of 51.4% (bottom 33%); research spending of 20.5% of revenue (top 38%) (its annual report).

What it rests on

cash less debt against assets16.0%top 43% of its family
cash from operations less capital spending against revenue-122.6%bottom 19% of its family
gross margin51.4%bottom 33% of its family
research spending against revenue20.5%top 38% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

7.8/10

What could actually drive growth from here?

top 23% of 105 in its family for growth drivers.

weight 33% of this tense · 77th percentile among 105 sector filers · read for its customers

From the record

Kestra Medical Technologies, Ltd.'s growth drivers, from the filed years to fiscal 2026: revenue grew 85% a year over the last three filed years against 85% over all 3, speeding up (top 43% of its family); the newest year grew 59.1% (top 10%); research spending grew 12.2% a year (top 31%); capital spending grew 69% a year (top 5%) (its annual reports). Kestra Medical Technologies, Ltd. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+0.0 points a yeartop 43% of its family
the newest year's revenue growth59.1%top 10% of its family
three-year growth of research spending12.2%top 31% of its family
three-year growth of capital spending69.0%top 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate

5.1/10

Did its newest year beat what its own record pointed to?

SI estimate 5.1/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 88 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 88 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 88 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Kestra Medical Technologies, Ltd.'s expectations vs reality is put at 5.1 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 88 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton KMTS · research, not advice